- Home
- MDAI vs MEIP Comparison
MDAI vs MEIP Comparison
Compare MDAI & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDAI
- MEIP
- Stock Information
- Founded
- MDAI 2013
- MEIP 2000
- Country
- MDAI United States
- MEIP United States
- Employees
- MDAI N/A
- MEIP N/A
- Industry
- MDAI Medical/Dental Instruments
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- MDAI Health Care
- MEIP Health Care
- Exchange
- MDAI Nasdaq
- MEIP Nasdaq
- Market Cap
- MDAI 51.5M
- MEIP 13.3M
- IPO Year
- MDAI N/A
- MEIP 2003
- Fundamental
- Price
- MDAI $2.68
- MEIP $2.35
- Analyst Decision
- MDAI Strong Buy
- MEIP Hold
- Analyst Count
- MDAI 2
- MEIP 1
- Target Price
- MDAI $4.75
- MEIP N/A
- AVG Volume (30 Days)
- MDAI 586.6K
- MEIP 21.6K
- Earning Date
- MDAI 08-11-2025
- MEIP 05-13-2025
- Dividend Yield
- MDAI N/A
- MEIP N/A
- EPS Growth
- MDAI N/A
- MEIP N/A
- EPS
- MDAI N/A
- MEIP N/A
- Revenue
- MDAI $29,962,000.00
- MEIP N/A
- Revenue This Year
- MDAI N/A
- MEIP N/A
- Revenue Next Year
- MDAI $15.14
- MEIP N/A
- P/E Ratio
- MDAI N/A
- MEIP N/A
- Revenue Growth
- MDAI 55.21
- MEIP 33.76
- 52 Week Low
- MDAI $0.82
- MEIP $1.46
- 52 Week High
- MDAI $3.25
- MEIP $4.10
- Technical
- Relative Strength Index (RSI)
- MDAI 74.34
- MEIP 55.80
- Support Level
- MDAI $2.07
- MEIP $2.32
- Resistance Level
- MDAI $2.22
- MEIP $3.15
- Average True Range (ATR)
- MDAI 0.16
- MEIP 0.20
- MACD
- MDAI 0.03
- MEIP 0.03
- Stochastic Oscillator
- MDAI 95.71
- MEIP 25.26
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.